8-K: Invivyd, Inc. Faces Nasdaq Delisting Threat Due to Low Stock Price

Invivyd, Inc. received a notification from Nasdaq that its common stock has fallen below the minimum bid price requirement for continued listing.

Summary

• Invivyd, Inc. received a deficiency letter from Nasdaq on April 21, 2025, because its stock price closed below $1.00 per share for 30 consecutive business days, violating Nasdaq's minimum bid price requirement.
• The company has until October 20, 2025, to regain compliance by maintaining a stock price of at least $1.00 for a minimum of ten consecutive business days.
• If Invivyd fails to meet this requirement, it may be eligible for an additional 180-day compliance period by transferring to The Nasdaq Capital Market and meeting other listing requirements, excluding the bid price requirement.
• Nasdaq will assess whether the company can cure the deficiency during the second compliance period.
• If compliance is not achieved, Nasdaq may issue a delisting notice, which the company can appeal.
• Invivyd intends to monitor its stock price and consider options to regain compliance, but there is no guarantee it will succeed.

Sentiment

Score: 3

Explanation: The news is negative as it indicates financial distress and potential delisting, but the company has a period to regain compliance.

Positives

• Invivyd has the opportunity to regain compliance with Nasdaq listing requirements by October 20, 2025.
• The company may be eligible for an additional 180-day compliance period if it transfers to The Nasdaq Capital Market.

Negatives

• Invivyd's stock price has fallen below the minimum bid price required for continued listing on The Nasdaq Global Market.
• There is no guarantee that Invivyd will be able to regain compliance with the minimum bid price requirement.
• Failure to regain compliance could result in delisting from Nasdaq.

Risks

• Invivyd may not be able to regain compliance with the minimum bid price requirement by October 20, 2025.
• Nasdaq may not grant the company relief from delisting, even if necessary.
• The company may not meet applicable Nasdaq requirements, even with relief.
• Delisting from Nasdaq could negatively impact the company's stock price and investor confidence.

Future Outlook

The company intends to actively monitor the closing bid price for the Common Stock and, as appropriate, will consider implementing available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement. However, there can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement.

Industry Context

Many biotech companies, especially those in the early stages of development, can face stock price volatility and the risk of falling below minimum listing requirements. This is often due to the inherent uncertainty in drug development and regulatory approvals.

Comparison to Industry Standards

• Companies like Sorrento Therapeutics and Ocugen have faced similar delisting warnings from Nasdaq due to low stock prices.
• Regaining compliance often involves strategies such as reverse stock splits, attracting new investment, or demonstrating significant progress in clinical trials or product development.
• The success of these strategies varies widely and depends on the company's specific circumstances and market conditions.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security if the company's financial situation worsens.
• The company's ability to raise capital and fund its operations may be negatively impacted.

Next Steps

• Invivyd will actively monitor the closing bid price for its common stock.
• Invivyd will consider implementing available options to resolve the deficiency and regain compliance with the Minimum Bid Price Requirement.

Key Dates

Keywords

Nasdaq, delisting, minimum bid price, compliance, Invivyd, IVVD, stock price